Thermo Fisher Scientific Industrial Theater Session

How expanded carrier screening research findings can drive future product development, in the area of preimplantation genetic testing
at the 5th IVF Worldwide Online Congress
Moderator: Yuval Yaron, Israel
AGENDA:
Expanded Carrier Screening research with Ion Torrent CarrierSeq ECS: How has it evolved? Colin Davidson, USA |
Comprehensive PGT-A + PGT-M: leveraging carrier screening research findings in addition to PGT-A analysis Alain Rico, France |
Next-generation sequencing and the Ion GeneStudio S5 System: advancing reproductive genetic research Joe Boland, USA |
Q&A Jose Luis Costa, Potugal |
Colin Davidson: Sr. Manager, Product Management, Reproductive Health NGS Assays
Product manager with a track record of successful next-generation sequencing product launches for the In Vitro Fertilization market. Manages the Ion Torrent ReproSeq PGS Kits and the Ion Torrent CarrierSeq ECS Kits for preimplantation genetic testing for aneuploidy (PGT-A) and expanded carrier screening (ECS), respectively.
Alain Rico: Sr. Manager, Global Market Development, Reproductive Health NGS
A specialist of the preimplantation genetic testing, at the origin of the first workflow for combined PGT-A, M and mitochondrial content on NGS. Responsible for KOL development, identifying and developing new reproductive health applications through collaborations and strategic partnerships, and general market development.
Joe Boland: Sr. Manager, Product Management, Ion GeneStudio™ Sequencing Systems
Over 25 years’ experience in the biotechnology field. Recently joined Thermo Fisher after 13 years at the National Cancer Institute in the United States where he was tasked with new technology assessment and application to cervical cancer research.
Jose Luis Costa: Director, Medical Affairs
Medical Affairs Director with a Scientific background in Molecular Diagnostics. Joined Thermo Fisher Scientific in 2020 after 14 years of translational research in Cancer Genetics and leading a Genomics Core Facility supporting both basic research and molecular diagnostics under CAP and ISO 15189 accreditation.